SunStar WHO approves Sinopharm vaccine for emergency use
SERBIA. In this Jan. 19, 2021 file photo, a medical worker poses with a vial of the Sinopharm s Covid-19 vaccine in Belgrade, Serbia. (AP)
+ May 08, 2021 THE World Health Organization (WHO) has granted emergency use listing (EUL) to the Sinopharm vaccine against coronavirus disease 2019 (Covid-19), facilitating its approval for emergency use worldwide and possible participation in the Covax Facility to promote vaccine equity.
The Sinopharm inactivated vaccine, called Sars-CoV-2 Vaccine (Vero Cell), is the sixth to receive WHO validation for safety, efficacy and quality, after those developed by Pfizer/BioNTech, AstraZeneca/Oxford (two vaccines), Serum Institute of India, and Janssen Pharmaceuticals (Johnson & Johnson).
WHO approves emergency use of Sinopharm vaccine
08 May 2021, 05:55 GMT+10
Geneva [Switzerland], May 8 (ANI): The World Health Organisation (WHO) on Friday approved the Chinese Sinopharm COVID-19 vaccine for emergency use, paving the way for it to be rolled out globally.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariangela Simao, WHO Assistant-Director General for Access to Health Products, in a statement.
Chinese COVID-19 vaccine Sinopharm gets WHO approval for emergency use
While WHO has listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen vaccines for emergency use, the Chinese vaccine got delayed recognition due to data related issues
PTI | May 8, 2021 | Updated 07:55 IST
In a big relief for China, the World Health Organisation (WHO) on Friday finally granted the conditional approval to its Sinopharm Covid-19 vaccine for emergency use, a move that could help Beijing step up its vaccine diplomacy amid the surge in coronavirus vaccines in several countries.
China has approved about five of its vaccines for emergency use and especially using Sinopharm and Sinovac vaccines for both at home and abroad. The Sinopharm vaccine was authorised by 45 countries and jurisdictions for use in adults, with 65 million doses administered, according to official media reports. But many countries hesitated using the vaccine as it has not secured recognition from the W
The World Health Organisation (WHO) on Friday approved the Chinese Sinopharm COVID-19 vaccine for emergency use, paving the way for it to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariangela Simao, WHO Assistant-Director General for Access to Health Products, in a statement. We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution, she added.
Department of Health Secretary Francisco Duque III (PCOO / MANILA BULLETIN FILE PHOTO)
The Health chief made the statement when asked if the government is still planning to return the donated Sinopharm vaccines to China after the World Health Organization (WHO) approved the vaccine brand for emergency use.
“I have already instructed the public health services office of the DOH to file with FDA for issuance of emergency use authorization for the Sinopharm donated vaccines so that there would be no need to return them,” said Duque in a press briefing on Saturday, May 8.
President Duterte on May 5 requested the Chinese Embassy to withdraw the Sinopharm donated vaccines after his inoculation drew public criticisms. The vaccine brand has yet to secure an EUA with the Philippine FDA.